IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer TA Mace, R Shakya, JR Pitarresi, B Swanson, CW McQuinn, S Loftus, ... Gut 67 (2), 320-332, 2018 | 471 | 2018 |
Pancreatic cancer-associated stellate cells promote differentiation of myeloid-derived suppressor cells in a STAT3-dependent manner TA Mace, Z Ameen, A Collins, S Wojcik, M Mair, GS Young, JR Fuchs, ... Cancer research 73 (10), 3007-3018, 2013 | 450 | 2013 |
Immune checkpoint inhibitors for the treatment of MSI-H/MMR-D colorectal cancer and a perspective on resistance mechanisms IH Sahin, M Akce, O Alese, W Shaib, GB Lesinski, B El-Rayes, C Wu British journal of cancer 121 (10), 809-818, 2019 | 299 | 2019 |
β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study S Lemeshow, HT Sørensen, G Phillips, EV Yang, S Antonsen, AH Riis, ... Cancer epidemiology, biomarkers & prevention 20 (10), 2273-2279, 2011 | 265 | 2011 |
Novel vaccine strategies to T-independent antigens GB Lesinski, MAJ Westerink Journal of microbiological methods 47 (2), 135-149, 2001 | 242 | 2001 |
Myeloid-derived suppressor cell inhibition of the IFN response in tumor-bearing mice BL Mundy-Bosse, GB Lesinski, AC Jaime-Ramirez, K Benninger, M Khan, ... Cancer research 71 (15), 5101-5110, 2011 | 235 | 2011 |
Enhanced bioavailability of lycopene when consumed as cis‐isomers from tangerine compared to red tomato juice, a randomized, cross‐over clinical trial JL Cooperstone, RA Ralston, KM Riedl, TC Haufe, RM Schweiggert, ... Molecular nutrition & food research 59 (4), 658-669, 2015 | 222 | 2015 |
The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse GB Lesinski, M Anghelina, J Zimmerer, T Bakalakos, B Badgwell, ... The Journal of clinical investigation 112 (2), 170-180, 2003 | 171 | 2003 |
A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells L Lin, S Deangelis, E Foust, J Fuchs, C Li, PK Li, EB Schwartz, ... Molecular cancer 9, 1-10, 2010 | 158 | 2010 |
Randomized phase 2 trial of the oncolytic virus pelareorep (Reolysin) in upfront treatment of metastatic pancreatic adenocarcinoma AM Noonan, MR Farren, SM Geyer, Y Huang, S Tahiri, D Ahn, S Mikhail, ... Molecular Therapy 24 (6), 1150-1158, 2016 | 154 | 2016 |
A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma KA Varker, JE Biber, C Kefauver, R Jensen, A Lehman, D Young, H Wu, ... Annals of surgical oncology 14, 2367-2376, 2007 | 153 | 2007 |
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4+ T cells from patients with GI malignancy BL Mundy-Bosse, GS Young, T Bauer, E Binkley, M Bloomston, MA Bill, ... Cancer Immunology, Immunotherapy 60, 1269-1279, 2011 | 151 | 2011 |
The small molecule curcumin analog FLLL32 induces apoptosis in melanoma cells via STAT3 inhibition and retains the cellular response to cytokines with anti-tumor activity MA Bill, JR Fuchs, C Li, J Yui, C Bakan, DM Benson, EB Schwartz, ... Molecular cancer 9, 1-12, 2010 | 147 | 2010 |
Lipocalin-2 promotes pancreatic ductal adenocarcinoma by regulating inflammation in the tumor microenvironment SB Gomez-Chou, AK Swidnicka-Siergiejko, N Badi, M Chavez-Tomar, ... Cancer research 77 (10), 2647-2660, 2017 | 137 | 2017 |
Vaccines against polysaccharide antigens GB Lesinski, J Westerink Current Drug Targets-Infectious Disorders 1 (3), 325-334, 2001 | 136 | 2001 |
Patients with pancreatic adenocarcinoma exhibit elevated levels of myeloid-derived suppressor cells upon progression of disease J Markowitz, TR Brooks, MC Duggan, BK Paul, X Pan, L Wei, Z Abrams, ... Cancer Immunology, Immunotherapy 64, 149-159, 2015 | 131 | 2015 |
α-Mangostin: anti-inflammatory activity and metabolism by human cells F Gutierrez-Orozco, C Chitchumroonchokchai, GB Lesinski, ... Journal of agricultural and food chemistry 61 (16), 3891-3900, 2013 | 131 | 2013 |
The potential of CAR T cell therapy in pancreatic cancer M Akce, MY Zaidi, EK Waller, BF El-Rayes, GB Lesinski Frontiers in immunology 9, 2166, 2018 | 127 | 2018 |
Preclinical investigation of the novel histone deacetylase inhibitor AR-42 in the treatment of cancer-induced cachexia YC Tseng, SK Kulp, IL Lai, EC Hsu, WA He, DE Frankhouser, PS Yan, ... Journal of the National Cancer Institute 107 (12), djv274, 2015 | 122 | 2015 |
A mathematical model for pancreatic cancer growth and treatments Y Louzoun, C Xue, GB Lesinski, A Friedman Journal of theoretical biology 351, 74-82, 2014 | 122 | 2014 |